Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 16, Issue 9, 2010, Pages 1598-1619

  Navaneethan, Udayakumar ^a   Shen, Bo ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Druginduced hepatitis; Extraintestinal manifestations; Liver transplantation; Primary sclerosing cholangitis; Restorative proctocolectomy; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; AUTOANTIBODY; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; FIBRINOLYTIC AGENT; HLA B8 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN G4; INFLIXIMAB; LAMIVUDINE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PURINE DERIVATIVE; SALAZOSULFAPYRIDINE; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ACUTE PANCREATITIS; AMINOTRANSFERASE BLOOD LEVEL; AMYLOIDOSIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BILE DUCT CARCINOMA; CHOLANGITIS; CHOLELITHIASIS; CHRONIC PANCREATITIS; CLINICAL TRIAL; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; CROHN DISEASE; DIGITAL IMAGING; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG WITHDRAWAL; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERITIS; FATIGUE; FATTY LIVER; FEVER; FLU LIKE SYNDROME; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL DISEASE; GRANULOMATOUS HEPATITIS; GRAVES DISEASE; HEPATITIS B; HEPATOMEGALY; HEPATOPANCREATOBILIARY MANIFESTATION; HUMAN; HYPERBILIRUBINEMIA; ILEOANAL ANASTOMOSIS; IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INTRAHEPATIC CHOLESTASIS; JAUNDICE; LIVER ABSCESS; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER HISTOLOGY; LIVER TOXICITY; LIVER TRANSPLANTATION; LYMPHADENOPATHY; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OBSTRUCTIVE JAUNDICE; PANCREATITIS; PATHOGENESIS; PHLEBITIS; PORTAL VEIN THROMBOSIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROCTOCOLECTOMY; PRURITUS; REVIEW; SCREENING; SIDE EFFECT; STEM CELL TRANSPLANTATION; SURGEON; SURVIVAL; T CELL LYMPHOMA; TOXIC HEPATITIS; ULCERATIVE COLITIS; VIRUS REACTIVATION; WEIGHT REDUCTION;

BILIARY TRACT DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER DISEASES; PANCREATIC DISEASES;

EID: 77956287746     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21219     Document Type: Review

References (248)

1. Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116-1122.
2. Ricart E, Panaccione R, Loftus EV Jr, et al. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2004;10:207-214.
3. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population- based study. Gastroenterology. 2005;129:827-836.
4. Mendoza JL, Lana R, Taxonera C, et al. Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis. Med Clin (Barc). 2005;125:297-300.
5. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore). 1976;55:401-412.
6. Olsson R, Danielsson A, Jarnerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 1991;100:1319-1323.
7. Smith M, Loe S. Sclerosing cholangitis: review of recent case reports and associated diseases and four new cases. Am J Surg. 1965;110:239-246.
8. Broomé U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006;26:31-40.
9. Loftus EV, Sandborn WJ, Lindor KD, et al. Interactions between chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis. 1997;3:288-302.
10. Faubion WA, Loftus EV, Sandborn WJ, et al. Pediatric "PSC-IBD": a descriptive report of associated inflammatory bowel disease among pediatric patients with PSC. J Pediatr Gastroenterol Nutr. 2001;33:296-300.
11. Loftus EV, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91-96.
12. Heuschen U, Hinz U, Allemeyer E, et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology. 2001;120:841-847.
13. Joo M, Abreu-e-Lima P, Farraye F, et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol. 2009;33:854-862.
14. Lundqvist K, Broomé U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum. 1997;40:451-456.
15. Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut. 1996;38:234-239.
16. Broome U, Lofberg R, Lundqvist K, et al. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis Colon Rectum. 1995;38:1301-1305.
17. Soetikno R, Lin O, Heidenreich P. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48-54.
18. Chapman RW, Marborgh BA, Rhodes JM, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut. 1980;21:870-877.
19. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med. 1995;332:924-933.
20. Helzberg JH, Peterson JM, Boyer JL. Improved survival with primary sclerosing cholangitis: a review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology. 1987;92:1869-1875.
21. Schrumpf E, Elgjo K, Fausa O, et al. Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol. 1980;15:689-697.
22. Shepherd HA, Selby WS, Chapman RW, et al. Ulcerative colitis and persistent liver dysfunction. Q J Med. 1983;52:503-513.
23. Rasmussen HH, Fallingborg JF, Mortensen PB, et al. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol. 1997;32:604-610.
24. Freeman K, Bennett AE, Lopez R, et al. Primary sclerosing cholangitis is associated with endoscopic and histologic backwash ileitis in patients with ileal pouch-anal anastomosis. Gastroenterology. 2008;134(suppl 1):A344.
25. Takikawa H, Manabe T. Primary sclerosing cholangitis in Japan-analysis of 192 cases. J Gastroenterol. 1997;32:134-137.
26. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 1997;92:204-211.
27. Bernstein CN, Eaden J, Steinhart AH, et al. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm Bowel Dis. 2002;8:356-361.
28. Bleday R, Lee E, Jessurun J, et al. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum. 1993;36:908-912.
29. Higashi H, Yanaga K, Marsh JW, et al. Development of colon cancer after liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis. Hepatology. 1990;11:477-480.
30. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813-1816.
31. Stahlberg D, Veress B, Tribukait B, et al. Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. Dis Colon Rectum. 2003;46:770-778.
32. Ludwig J, Barham SS, La Russo NF, et al. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology. 1981;1:632-640.
33. MacCarty RL, La Russo NF, May GR, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis: cholangiographic appearances. Radiology. 1985;156:43-46.
34. Broomé U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38:610-615.
35. Rabinovitz M, Gavaler JS, Schade RR, et al. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects. Hepatology. 1990;11:7-11.
36. Farrant JM, Doherty DG, Donaldson PT, et al. Amino acid substitutions at positions 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology. 1992;16:390-395.
37. Olerup O, Olsson R, Hultcrantz R, et al. HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology. 1995;108:870-878.
38. Saarinen S, Olerup O, Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2000;95:3195-3199.
39. Mulder AH, Horst G, Haagsma EB, et al. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology. 1993;17:411-417.
40. Bansi DS, Fleming KA, Chapman RW. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass. Gut. 1996;38:384-389.
41. Terjung B, Spengler U. Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases. Clin Rev Allergy Immunol. 2005;28:115-133.
42. Terjung B, Spengler U, Sauerbruch T, et al. "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology. 2000;119:310-322.
43. Mandal A, Dasgupta A, Jeffers L, et al. Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium. Gastroenterology. 1994;106:185-192.
44. O'Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis. 2006;26:3-21.
45. Worthington J, Cullen S, Chapman R. Immunopathogenesis of primary sclerosing cholangitis. Clin Rev Allergy Immunol. 2005;28:93-103.
46. Fausa O, Schrumpf E, Elgio K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis. 1991;11:31-39.
47. Aoki CA, Bowlus CL, Gershwin ME. The immunobiology of primary sclerosing cholangitis. Autoimmun Rev. 2005;4:137-143.
48. Kono K, Ohnishi K, Omata K, et al. Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits. Gastroenterology. 1988;94:787-796.
49. Bjornsson ES, Kilander AF, Olsson RG. Bile duct bacterial isolates in primary sclerosing cholangitis and certain other forms of cholestasis - a study of bile cultures from ERCP. Hepatogastroenterology. 2000;47:1504-1508.
50. Terjung B, Muennich M, Gottwein J, et al. Identification of myeloid-specific tubulin-beta isotype 5 as target antigen of antineutrophil cytoplasmic antibodies in autoimmune liver disorders. Hepatology. 2005;42(suppl 1):288A.
51. Erickson HP. FtsZ, a prokaryotic homolog of tubulin? Cell. 1995;80:367-370.
52. Terjung B, Spengler U. Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"? Clin Rev Allergy Immunol. 2009;36:40-51.
53. Tischendorf JJ, Hecker H, Kruger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007;102:107-114.
54. Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology. 1989;10:430-436.
55. Talwalkar JA, Lindor KD. Primary sclerosing cholangitis. Inflamm Bowel Dis. 2005;11:62-72.
56. Heikius B, Niemela S, Lehtola J, et al. Hepatobiliary and coexisting pancreatic duct abnormalities in patients with inflammatory bowel disease. Scand J Gastroenterol. 1997;32:153-161.
57. Navaneethan U, Remzi FH, Nutter B, et al. Risk Factors for Abnormal Liver Function Tests in Patients With Ileal Pouch-Anal Anastomosis for Underlying Inflammatory Bowel Disease. Am J Gastroenterol. 2009;104:2467-2475.
58. MacCarty RL, LaRusso NF, Wiesner RH, et al. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology. 1983;149:39-44.
59. Moreno Luna LE, Gores GJ. Advances in the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver Transpl. 2006;12 (11 Suppl 2):S15-19.
60. Fulcher AS, Turner MA, Franklin KJ, et al. Primary sclerosing cholangitis: evaluation with MR cholangiography - a case-control study. Radiology. 2000;215:71-80.
61. Angulo P, Pearce DH, Johnson CD, et al. Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol. 2000;33:520-527.
62. Moff SL, Kamel IR, Eustace J, et al. Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance Cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc. 2006;64:219-223.
63. Berstad AE, Aabakken L, Smith HJ, et al. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2006;4:514-520.
64. Textor HJ, Flacke S, Pauleit D, et al. Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. Endoscopy. 2002;34:984-990.
65. Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol. 2003;98:1155-1158.
66. Charatcharoenwitthaya P, Enders FB, Halling KC, et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology. 2008;48:1106-1117.
67. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242:451-458.
68. Parsi MA, Li A, Li CP, et al. DNA methylation alterations in endoscopic retrograde cholangiopancreatography brush samples of patients with suspected pancreaticobiliary disease. Clin Gastroenterol Hepatol. 2008;6:1270-1278.
69. Cohen S, Bacon BR, Berlin JA, et al. National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14-16, 2002. Gastrointest Endosc. 2002;56:803-809.
70. Porayko MK, Wiesner RH, LaRusso NF, et al. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology. 1990;98:1594-1602.
71. Farrant JM, Hayllar KM, Wilkinson ML, et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology. 1991;100:1710-1717.
72. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, et al. Natural history of primary sclerosing cholangitis and prognostic value of Cholangiography in a Dutch population. Gut. 2002;51:562-566.
73. Ludwig J, LaRusso NF, Wiesner RH. Primary sclerosing cholangitis. In: RL Peters, JG Craig, eds. Contemporary issues in surgical pathology: liver pathology. New York: Churchill Livingstone; 1986:193-213.
74. Zein CO, Lindor KD, Angulo P. Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology. 2004;39:204-210.
75. Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis obviates the need for liver histology. Mayo Clinic Proc. 2000;75:688-694.
76. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36:321-327.
77. Fevery J, Verslype C, Lai G, et al. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci. 2007;52:3123-3135.
78. Boberg KM, Jebsen P, Clausen OP, et al. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2006;45:568-574.
79. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med. 1997;336:691-695.
80. Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129:1464-1472.
81. Cullen SN, Rust C, Fleming K, et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol. 2008;48:792-800.
82. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50:808-814.
83. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001;134:89-95.
84. Baluyut AR, Sherman S, Lehman GA, et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc. 2001;53:308-312.
85. Tischendorf JJ, Meier PN, Strassburg CP, et al. Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scand J Gastroenterol. 2006;41:1227-1234.
86. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242:451-458.
87. Graziadei IW, Wiesner RH, Marotta PJ, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology. 1999;30:1121-1127.
88. Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology. 1999;29:1050-1056.
89. Wee A, Ludwig J, Coffey RJ Jr, et al. Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hum Pathol. 1985;16:719-726.
90. Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis:prevalence and natural history. Hepatology. 2002;35:1494-1500.
91. Björnsson E, Boberg KM, Cullen S, et al. Patients with small duct primary sclerosing cholangitis have a favorable long-term prognosis. Gut. 2002;51:731-735.
92. Broomé U, Glaumann H, Lindstöm E, et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol. 2002;36:586-589.
93. Björnsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008;134:975-980.
94. Saldeen K, Friman S, Olausson M, et al. Follow-up after liver transplantation for primary sclerosing cholangitis: effects on survival, quality of life, and colitis. Scand J Gastroenterol. 1999;34:535-540.
95. Befeler AS, Lissoos TW, Schiano TD, et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation. 1998;65:393-396.
96. Riley TR, Schoen RE, Lee RG, et al. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroeneterol. 1997;92:279-282.
97. Papatheodoridis GV, Hamilton M, Mistry PK, et al. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut. 1998;43:595-596.
98. Verdonk RC, Dijkstra G, Haagsma EB, et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant. 2006;6:1422-1429.
99. Zins BJ, Sandborn WJ, Penna CR, et al. Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. Am J Gastroenterol. 1995;90:2177-2180.
100. Freeman K, Shao Z, Remzi FH, et al. Impact of orthotopic liver transplant for primary sclerosing cholangitis on chronic antibiotic refractory pouchitis. Clin Gastroenterol Hepatol. 2008;6:62-68.
101. Mathis KL, Dozois EJ, Larson DW, et al. Ileal pouch-anal anastomosis and liver transplantation for ulcerative colitis complicated by primary sclerosing cholangitis. Br J Surg. 2008;95:882-886.
102. Poritz LS, Koltun WA. Surgical management of ulcerative colitis in the presence of primary sclerosing cholangitis. Dis Colon Rectum. 2003;46:173-178.
103. Cangemi JR, Wiesner RH, Beaver SJ, et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology. 1989;96:790-794.
104. Mikkola K, Kiviluoto T, Riihelä M, et al. Liver involvement and its course in patients operated on for ulcerative colitis. Hepatogastroenterology. 1995;42:68-72.
105. Lepistö A, Kivistö S, Kivisaari L, et al. Primary sclerosing cholangitis: outcome of patients undergoing restorative proctocolecetomy for ulcerative colitis. Int J Colorectal Dis. 2009;24:1169-1174.
106. Woodward J, Neuberger J. Autoimmune overlap syndromes. Hepatology. 2001;33:994-1002.
107. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/ sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33:544-553.
108. Abdo AA, Bain VG, Kichian K, et al. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology. 2002;36:1393-1399.
109. Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005;100:1516-1522.
110. Perdigoto R, Carpenter H, Czaja A. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Heparol. 1992;14:325-331.
111. Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology. 2001;34:659-665.
112. de Suray N, Van Beers B, Sempoux C, et al. Autoimmune pancreatitis, sclerosing cholangitis, liver inflammatory pseudotumors, retroperitoneal fibrosis, lymphadenopathy, and sialoadenitis in a single patient: a multifaced expression of a hitherto unrecognized systemic autoimmune syndrome? Pancreas. 2009;38:476-478.
113. Bjornsson E, Chari ST, Smyrk TC, et al. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology 2007;1547-1554.
114. Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006;101:2070-2075.
115. Zhang LL, J, Abraham SC, et al. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Modern Pathol. 2009;22:1480.
116. Dastis SN, Latinne D, Sempoux C, et al. Ulcerative colitis associated with IgG4 cholangitis: similar features in two HLA identical siblings. J Hepatol. 2009;51:601-605.
117. Webster GJ, Pereira SP, Chapman RW. Autoimmune pancreatitis/ IgG4-associated cholangitis and primary sclerosing cholangitis - overlapping or separate diseases? J Hepatol. 2009;51:398-402.
118. Keljo DJ, Sugerman KS. Pancreatitis in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1997;25:108-112.
119. Weber P, Seibold F, Jenss H. Acute pancreatitis in Crohn's disease. J Clin Gastroenterol. 1993;17:286-291.
120. Lankish PG, Droge M, Gottesleben F. Drug induced acute pancreatitis: incidence and severity. Gut. 1995;37:565-567.
121. Deprez P, Descamps CH, Fiasse R. Pancreatitis induced by 5-aminosalicylic acid. Lancet. 1989;ii:445-446.
122. Barthet M, Hastier P, Bernard JP, et al. Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? Am J Gastroenterol. 1999;94:2141-2148.
123. Herrlinger KR, Stange EF. The pancreas and inflammatory bowel diseases. Int J Pancreatol. 2000;27:171-179.
124. Altman HS, Philips G, Bank S, et al. Pancreatitis associated with duodenal Crohn's disease. Am J Gastroenterol. 1983;78:174-177.
125. Legge DA, Hofman HN, Carlson HC. Pancreatitis as a complication of regional enteritis of the duodenum. Gastroenterology. 1971;61:834-837.
126. Matsumoto T, Matsui T, Iida M, et al. Acute pancreatitis as a complication of Crohn's disease. Am J Gastroenterol. 1989;84:804-807.
127. Spiess SE, Braun M, Vogelzang RL, et al. Crohn's disease of the duodenum complicated by pancreatitis and common bile duct obstruction. Am J Gastroenterol. 1992;87:1033-1036.
128. Gschwantler M, Kogelbauer G, Klose W, et al. The pancreas as a site of granulomatous inflammation in Crohn's disease. Gastroenterology. 1995;108:1246-1249.
129. Kazumori H, Ashizawa N, Moriyama N, et al. Primary sclerosing pancreatitis and cholangitis. Int J Pancreatol. 1998;24:123-127.
130. Moolsintong P, Loftus EV, Chari ST, et al. Acute pancreatitis in patients with Crohn's disease: clinical features and outcomes. Inflamm Bowel Dis. 2005;11:1080-1084.
131. Seyrig JA, Jian R, Modigliani R, et al. Idiopathic pancreatitis associated with inflammatory bowel disease. Dig Dis Sci. 1985;30:1121-1126.
132. Heikius B, Niemela S, Lehtola J, et al. Pancreatic duct abnormalities and pancreatic function in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1996;31:517-523.
133. Katz S, Bank S, Greenberg R, et al. Hyperamylasemia in inflammatory bowel disease. J Clin Gastroenterol. 1988;6:627-630.
134. Barthet M, Lesavre N, Desplats S, et al. Frequency and characteristics of pancreatitis in patients with inflammatory bowel disease. Pancreatology. 2006;6:464-471.
135. Ball WP, Baggenstoss AH, Bargen JA. Pancreatic lesions associated with chronic ulcerative colitis. Arch Pathol. 1950;50:345-358.
136. Rasmussen HH, Fonager K, Sorensen HT, et al. Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1999;34:199-201.
137. Barthet M, Dubucquoy L, Garcia S, et al. Pancreatic changes in TNBS-induced colitis in mice. Gastroenterol Clin Biol. 2003;27:895-900.
138. Angelini G, Cavallini G, Bovo P, et al. Pancreatic function in chronic inflammatory bowel disease. Int J Pancreatol. 1988;3:185-193.
139. Hegnhoj J, Hansen CP, Rannem T, et al. Pancreatic function in Crohn's disease. Gut. 1990;31:1076-1979.
140. Chapin LE, Scudamore HH, Baggenstoss AH, et al. Regional enteritis- associated visceral charges. Gastroenterology. 1956;30:404-415.
141. Stocker W, Otte M, Ulrich S, et al. Autoimmunity to pancreatic juice in Crohn's disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. Scand J Gastroenterol Suppl. 1987;139:41-52.
142. Targan SR, Landers CJ, Cobb L, et al. Perinuclear anti-neutrophil cytoplasmic antibodies are spontaneously produced by mucosal B cells of ulcerative colitis patients. J Immunol. 1995;155:3262-3267.
143. Hill GL, Mair WS, Goligher JC. Gallstones after ileostomy and ileal resection. Gut. 1975;16:932-936.
144. Whorwell PJ, Hawkins R, Dewbury K, et al. Ultrasound survey of gallstones and other hepatobiliary disorders in patients with Crohn's disease. Dig Dis Sci. 1984;29:930-933.
145. Lorusso D, Leo S, Mossa A, et al. Cholelithiasis in inflammatory bowel disease: a case-control study. Dis Colon Rectum. 1990;33:791-794.
146. Lapidus A, Bangstad M, Astrom M, et al. The prevalence of gallstone disease in a defined cohort of patients with Crohn's disease. Am J Gastroenterol. 1999;94:1261-1266.
147. Fraquelli M, Losco A, Visentin S, et al. Gallstone disease and related risk factors in patients with Crohn disease: analysis of 330 consecutive cases. Arch Intern Med. 2001;161:2201-2204.
148. Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single centre. J Clin Gastroenterol. 2003;36:417-420.
149. Dowling RH, Bell GD, White J. Lithogenic bile in patients with ileal dysfunction. Gut. 1972;13:415-420.
150. Lapidus A, Einarsson K. Effects of ileal resection on biliary lipids and bile acid composition in patients with Crohn's disease. Gut. 1991;32:1488-1491.
151. Lapidus A, Einarsson C. Bile composition in patients with ileal resection due to Crohn's disease. Inflamm Bowel Dis. 1998;4:89-94.
152. Brink MA, Slors JFM, Keulemans YCA, et al. Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn's disease. Gastroenterology. 1999;116:1420-1427.
153. Parente F, Pastore L, Bargiggia S, et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology. 2007;45:1267-1274.
154. Damiao AO, Sipahl AM, Vezozzo DP, et al. Gallbladder hypokinesis in Crohn's disease. Digestion. 1997;58:458-463.
155. Annese V, Vantrappen G. Gallstones in Crohn's disease: another hypothesis. Gut. 1994;35:1676.
156. Pitt HA, King W, Mann L, et al. Increased risk of cholelithiasis with prolonged total parenteral nutrition. Am J Surg. 1983;145:106-112.
157. Jackson LM, O'Gorman PJ, O'Connell J, et al. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM. 1997;90:183-188.
158. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004;53:542-548.
159. Liappis AP, Roberts AD, Schwartz AM, et al. Thrombosis and infection: a case of transient anti-cardiolipin antibody associated with pylephlebitis. Am J Med Sci. 2003;325:365-368.
160. Sanghavi P, Paramesh A, Dwivedi A, et al. Mesenteric Arterial Thrombosis as a complication of Crohn's disease. Dig Dis Sci. 2001; 46:2344-2346.
161. Vakil N, Hayne G, Sharma A, et al. Liver abscess in Crohn's disease. Am J Gastroenterol. 1994;89:1090-1095.
162. Margalit M, Elinav H, Ilan Y, et al. Liver abscess in inflammatory bowel disease: Report of two cases and review of the literature. J Gastroenterol Hepatol. 2004;19:1338-1342.
163. Hazzan D, Fishman E, Heller E, et al. Liver abscess in Crohn's disease: a report of three cases. Mount Sinai J Med. 2004;71:351-355.
164. Plemmons RM, Dooley DP, Longfield RN. Septic thrombophlebitis of the portal vein (Pylephlebitis): diagnosis and management in the modern era. Clin Infec Dis. 1995;21:1114-1120.
165. Baker ME, Remzi F, Einstein D, et al. CT depiction of portal vein thrombi after creation of ileal pouch-anal anastomosis. Radiology. 2003;227:73-79.
166. Remzi FH, Fazio VW, Oncel M, et al. Portal vein thrombi after restorative proctocolectomy. Surgery. 2002;132:655-661.
167. Ball CG, MacLean AR, Buie WD, et al. Portal vein thrombi after ileal pouch-anal anastomosis: its incidence and association with pouchitis. Surg Today. 2007;37:552-557.
168. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641-649.
169. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+T lymphocytes. J Clin Invest. 2003;111:1133-1145.
170. Gisbert JP, Luna M, González-Lama Y, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007;13:1106-1114.
171. Romagnuolo J, Sadowski DC, Lalor E, et al. Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol. 1998;12:479-483.
172. Bouchnik Y, Lemann M, Mary J-Y, et al. Long-term followup of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996;347:215-219.
173. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485-489.
174. Shorey J, Schenker S, Suki WN, et al. Hepatotoxicity of mercaptopurine. Arch Intern Med. 1968;122:54-58.
175. Dubinsky MC, Yang HY, Hassard PV, et al. 6-MP metabolite pro- files provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002; 122:904-915.
176. Cuffari C, Hunt S, Bayless T. Utilization of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut. 2001;48:642-646.
177. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut. 1996; 39:401-406.
178. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118:1025-1030.
179. Shaye OA, Yadegari M, Abreu MT, et al. Hepatotoxicity of 6-mercaptopurine (6-MP) and azathioprine (AZA) in adult IBD patients. Am J Gastroenterol. 2007;102:2488-2494.
180. Lichtenstein GR, Abreu MT, Cohen R, et al; American Gastroenterological Association. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:935-939.
181. Farrell GC. Drug-induced liver disease, 1st ed. Singapore: Churchill Livingstone; 1994.
182. DeLeve LD, Wang X, Kuhlenkamp JF, et al. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology. 1996;23:589-599.
183. Russmann S, Zimmermann A, Krahenbuhl S, et al. Venoocclusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol. 2001;13:287-290.
184. Daniel F, Cadranel JF, Seksik P, et al. Azathioprine-induced nodular regenerative hyperplasia in IBD patients. Gastroenterol Clin Biol. 2005;29:600-603.
185. Bertino J. The mechanism of action of the folate antagonists in man. Cancer Res. 1963;23:1286.
186. Alarcon GS, Goodman TA, Polisson RP. Methotrexate: adverse reactions and major toxicities. Rheumatic Dis Clin North Am. 1994;20:513-528.
187. Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum. 1994;37:316-328.
188. Kremer JM, Galivan J, Streckfuss A, et al. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum. 1986;29:832-835.
189. Sandborn WJ. A review of immunemodifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91:423-433.
190. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med. 1995;332:292-297.
191. Kozarek RA, Bredfeldt JE, Rosoff LE, et al. Does chronic methotrexate (MTX) cause liver toxicity when used for refractory inflammatory bowel disease (IBD)? Gastroenterology. 1991;100:A221 (Abstract).
192. Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of long term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95:3150-3156.
193. Wahed M, Louis-Auguste JR, Baxter LM, et al. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther. 2009;30:614-620.
194. Roenigk HH Jr, Auerbach R, Mailbach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 1998;38:478-485.
195. Taffet SL, Das KM. Sulfasalazine: adverse effects and desensitization. Dig Dis Sci. 1983;28:833-842.
196. Hanauer SB, Meyers S, Sachar DB. The pharmacology of antiinflammatory drugs in inflammatory bowel disease. In: Kirsner JB, Shorter RG, editors. Inflammatory bowel disease, 4th ed. Baltimore: Williams & Wilkins; 1995;643-663.
197. Teo L, Tan E. Sulphasalazine-induced DRESS. Singapore Med J. 2006;47:237-239.
198. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. BMJ. 1989;298:82-86.
199. Hautekeete ML, Bourgeois N, Potvin P, et al. Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine. Gastroenterology. 1992;103:1925-1927.
200. Stochus B, Meybehm M, Spengler U, et al. Cholestasis associated with mesalazine therapy in a patient with Crohn's disease. J Hepatol. 1997;26:425-428.
201. Deltenre P, Berson A, Marcellin P, et al. Mesalazine (5-aminosalicylic acid) induced chronic hepatitis. Gut. 1999;44:886-888.
202. Nahon S, Cadranel JF, Chazouilleres O, et al. Liver and inflammatory bowel disease. Gastroenterol Clin Biol. 2009;33:370-381.
203. Stacey NH, Kotecka B. Inhibition of taurocholate and ouabain transport in isolated rat hepatocytes by cyclosporin A. Gastroenterology. 1988;95:780-786.
204. Parrott NR, Taylor RM, Venables CW, et al. Treatment of Crohn's disease in relapse with cyclosporin A. Br J Surg. 1988;75:1185-1188.
205. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis. 2004;10:73-78.
206. Germano V, Picchianti Diamanti A, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis. 2005;64:1519-1520.
207. Schiemann U, Kellner H. Gastrointestinal side effects in the therapy of rheumatologic diseases. Z Gastroenterol. 2002;40:937-943.
208. Mastroianni A, Minutilli E, Mussi A, et al. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol. 2005;153:531-536.
209. Menghini V. Amindra S. Infliximab associated reversible cholestatic liver disease. Mayo Clin Proc. 2001;76:84-86.
210. Tobon GJ, Canas C, Jaller JJ, et al. Serious liver disease induced by infliximab. Clin Rheumatol. 2006;26:578-581.
211. Ierardi E, Valle ND, Nacchiero MC, et al. Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin Drug Investig. 2006;26:673-676.
212. Jarret S, Cunnane G, Conaghan P, et al. Anti-tumor necrosis factor therapy-induced vasculitis: case series. J Rheumatol. 2003;30:2287-2291.
213. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-1811.
214. Biancone L, Pavia M, Del Vecchio Blanco G, et al. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis. 2001;7:287-294.
215. Ueno Y, Tanaka S, Shimamoto M, et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Digest Dis Sci. 2005;50:163-166.
216. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004;53:1363-1365.
217. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001;19:65-91.
218. Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med. 2000;223:241-257.
219. Papa A, Mocci G, Bonizzi M, et al. Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol. 2009;104:1575-1586.
220. Ferri C, Ferraccioli G, Ferrari D, et al. Safety of anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol. 2008;35:1944-1949.
221. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol. 2006;21:1366-1371.
222. Bajaj JS, Saeian K, Varma RR, et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol. 2005;100:1121-1125.
223. Villarreal HA, Wells LD, Neusschwander-Tetri BA, Azathioprine induced acute pancreatitis in mice. Gastroenterolgy. 1995;108(suppl):A398.
224. Mardini HE. Azathioprine-induced pancreatitis in Crohn's disease: a smoking gun or guilt by association. Aliment Pharmacol Ther. 2005;15;21:195.
225. Alexander S, Dowling D. Azathioprine pancreatitis in inflammatory bowel disease and successful subsequent treatment with mercaptopurine. Intern Med J. 2005;35:570-571.
226. Lamers CBHW, Griffioen G, van Hegezand RA, et al. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol. 1999;S230:111-115.
227. Sturdevant RA, Singleton JW, Deren JL, et al. Azathioprine-related pancreatitis in patients with Crohn's disease. Gastroenterology. 1979; 77(4 Pt 2):883-886.
228. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881.
229. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T-cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265-267.
230. Navarro JT, Ribera JM, Mate JL, et al. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma. 2003;44:531-533.
231. Mittal S, Milner BJ, Johnston PW, et al. A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur J Haematol. 2006;76:531-534.
232. Keller KM. Hepatosplenic T-cell lymphoma in a 15-year old boy with ulcerative colitis treated with azathioprine for 9 years. J Pediatr Gastroenterol Nutr. 2007;44:e259.
233. Shale M, Kanfer E, Panaccione R, et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut. 2008;57:1639-1641.
234. Tey SK, Marlton PV, Hawley CM, et al. Post-transplant hepatosplenic T-cell lymphoma successfully treated with Hyper CVAD regimen. Am J Hematol. 2008;83:330-333.
235. Konuma T, Ooi J, Takahashi S, et al. Allogeneic stem cell transplantation for hepatosplenic gammadelta T-cell lymphoma. Leuk Lymphoma. 2007;48:630-632.
236. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm175843.htm
237. Grandval PH, Barthet M, Gargia S, et al. Pseudotumorous chronic pancreatitis associated with inflammatory bowel disease. Dig Dis Sci. 2001;46:898-900.
238. Sahel J, Barthet M, Gasmi M. Autoimmune pancreatitis: increasing evidence for a clinical entity with various patterns. Eur J Gastroenterol Hepatol. 2004;16:1265-1268.
239. Ravi K, Chari ST, Vege SS, et al. Inflammatory bowel disease in the setting of autoimmune pancreatitis. Inflamm Bowel Dis. 2009;15:1326-1330.
240. Xiao WB, Liu YL. Primary biliary cirrhosis and ulcerative colitis: a case report and review of literature. World J Gastroenterol. 2003;9:878-880.
241. Koulentaki M, Koutroubakis IE, Petinaki E, et al. Ulcerative colitis associated with primary biliary cirrhosis. Dig Dis Sci. 1999;44:1953-1956.
242. Lever E, Balasubramanian K, Condon S, et al. Primary biliary cirrhosis associated with ulcerative colitis. Am J Gastroenterol. 1993;88:945-947.
243. Riegler G, D'Inca R, Sturniolo GC, et al. Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. Scand J Gastroenterol. 1998;33:93-98.
244. de Dombal FT, Goldie W, Watts JMcK, Goligher JC. Hepatic histological changes in ulcerative colitis. Scand J Gastroenterol. 1966;1:220-227.
245. Greenstein AJ, Sachar DB, Panday AK, et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore). 1992;71:261-270.
246. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis. 2001;7:295-300.
247. Callen JP, Soderstrom RM. Granulomatous hepatitis associated with salicylazosulfapyridine therapy. South Med J. 1978;71:1159-1160.
248. Charatcharoenwitthaya P, Lindor KD. Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up. Clin Gastroenterol Hepatol. 2007;5:32-36.